Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio

Disappointing clinical trial results from Sanofi and Regeneron raise questions about the future role that certain drugs might have in treating asthma and other inflammatory related diseases.
Source: Kristoffer Tripplaar/Sipa via AP

Sanofi (SNY) and Regeneron Pharmaceuticals () said Friday that a monoclonal antibody drug targeting a protein called IL-33 provided no additional benefit to asthma patients when added to the already approved drug Dupixent.

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readPsychology
It’s Not Just Bosses Who Harass Health Workers: Hospitals Start Addressing Patients’ ‘Egregious’ Behavior
There's growing awareness that it’s not just bosses and colleagues who sexually harass health care workers. Often, it’s the patients who are doing the harassing.
STAT5 min readPolitics
Opinion: Wider Use Of Assisted Outpatient Treatment Could Help Individuals With Mental Illness
Many states still rely on laws that require individuals to become dangerous to themselves or others before they can be treated without their consent. We need laws that that prevent…
STAT9 min readWellness
‘The Switch’ Was Supposed To Be A Major Step Toward Eradicating Polio. Now It’s A Quandary
A change in polio vaccination policies was supposed to put the world on a better footing to finally eliminate a global scourge. It's gotten complicated.